Eric K. Singhi, MD

Eric K. Singhi, MD, is an assistant professor in the Department of General Oncology in the Division of Cancer Medicine and in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston.

Articles

Future Avenues of Research in Advanced NSCLC

October 20th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.

Eye-Catching Data From the 2025 World Conference on Lung Cancer

October 20th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.

Navigating Immunotherapy in Advanced NSCLC After Early-Stage IO Therapy

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

5-Year EMPOWER-Lung 3 Data for Cemiplimab Plus Chemo in Advanced NSCLC

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Managing Immune-Related AEs in NSCLC

October 7th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.

How Cemiplimab Plus Chemo Has Affected First-Line NSCLC Management, Including Squamous Histology

October 7th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

Treatment Decision-Making and Sequencing Factors in Advanced Non–Small Cell Lung Cancer

September 29th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss treatment and sequencing considerations in advanced non–small cell lung cancer.

Dr Singhi on Responsibly and Effectively Leveraging Social Media for Patient Education in Oncology

September 8th 2025

Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.

Exploring the Latest in EGFR-Mutant Lung Cancer With Drs Ramalingam and Raez

September 8th 2025

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Dr Singhi on the Rationale for Evaluating Lurbinectedin Plus Atezolizumab in ES-SCLC

July 15th 2025

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.

Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

February 21st 2025

Dr. Eric Singhi presents preliminary findings from the Phase I/II SOHO-01 trial, demonstrating that the oral HER2-targeted tyrosine kinase inhibitor BAY 2927088 achieves high response rates and durable disease control in patients with pretreated HER2-mutant NSCLC, with a manageable safety profile.

Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer

October 4th 2024

Eric Kumar Singhi, MD, discusses the identification of current care gaps and unmet needs in small cell lung cancer.

Dr Singhi on the Potential Benefit of the ADRIATIC Study Findings in LS-SCLC

August 29th 2024

Eric Kumar Singhi, MD, discusses unmet needs in the management of small cell lung cancer, highlighting how the ADRIATIC study addressed these needs.

Dr Singhi on Areas of Interest in Metastatic Lung Cancer Research

August 26th 2024

Eric Kumar Singhi, MD, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer.

Dr Eric Singhi Navigates Advocacy, Mentorship, and More in NSCLC Management

April 23rd 2024

Eric K. Singhe, MD, of The University of Texas MD Anderson Cancer Center, discusses the journey of non–smell cell lung cancer treatment through mentorship, advocacy, and more.